ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0966

Comparison of Outcomes for Paired Kidney Exchange, End Chain, and Directed Donor Living-Donor Kidney Transplants

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Bankulla, Misha R, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Kancherla, Pranav S., Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Shah, Divyash V., Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Chandrashekar, Sneha, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Tandukar, Srijan, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Background

Living donor kidney transplants (LDKT) comprise roughly a quarter of all kidney transplants in the US. Directed donor LDKT (D-LDKT) remains the most common, but rising rates of Paired Kidney Exchange LDKT (PKE-LDKT) and End Chain LDKT (EC-LDKT) have expanded access for many waitlisted patients. This study compares graft and patient survival across these LDKT sources.

Methods

We evaluated adult LDKT recipients at the University of Pennsylvania between 1/1/2015 and 11/30/2023. Clinical data on recipient, donor, and transplant characteristics were collected from electronic medical records. Any graft or patient loss was analyzed using Kaplan Meier survival analysis.

Results

Donor age, cold ischemia time, zero HLA mismatch (all p<0.001), and recipient pre-emptive transplant (p=0.002) differ significantly across LDKT groups. On Kaplan Meier analysis, there is no difference in patient survival (p=0.12; Fig 1) or kidney graft survival (p=0.81; Fig 2).

Conclusion

Our study shows similar graft and patient outcomes across D-LDKT, PKE-LDKT and EC-LDKT pathways. Increased participation of transplant programs in PKE and EC-LDKT can improve access to LDKT for more waitlisted patients.

Baseline Characteristics of the Cohort
 Directed Donor LDKT (N = 413)NKR End Chain (N = 49)NKR KPD (N = 124)P-value
Recipient age (years)49 (14)49 (12)49 (14)0.79
Recipient female gender143 (34.6%)25 (51.0%)53 (42.7%)0.05
Recipient pre-emptive transplant248 (60.0%)18 (36.7%)60 (48.4%)0.002
Donor age (years)46 (12)55 (12)42 (12)< 0.001
Donor female gender279 (67.6%)33 (67.3%)75 (60.5%)0.78
Cold ischemia time1.6 (1.6)4.7 (3.4)9.8 (4.6)< 0.001
Zero HLA mismatch19 (4.6%)0 (0.0%)2 (1.6%)<0.001

Fig 2

Fig 1

Digital Object Identifier (DOI)